Otsuka And Prasco Laboratories Sign A Commercial Supply Agreement For PLETAL Tablets
10/19/2005 5:11:51 PM
Prasco Laboratories, a privately-held pharmaceutical company located in Cincinnati, Ohio, announced today that--under a commercial supply agreement with Otsuka America Pharmaceutical, Inc.--it has initiated shipments of Cilostazol Tablets in the 50 mg and 100 mg strengths. Cilostazol is the authorized generic version of Otsuka's PLETAL(R), which is a PDE-111 inhibitor indicated for the treatment of intermittent claudication (IC). Prasco has received the rights to market 50 mg and 100 mg strength Cilostazol in the United States.
comments powered by